Will New Business Models Enhance or Endanger Drug Discovery?

The most successful biotechs of the past quarter century have been companies that established relatively large, cutting edge research programs, such as Biogen, Immunex, and Genentech. I’ll refer to this as the B.I.G. model. These companies were able to hire young, innovative scientists by promising them a certain degree of intellectual freedom to pursue research projects and build their reputations on the results. While these researchers were well compensated financially for their efforts, I don’t...
Flag this


There are currently no comments. Add a new comment!

Post a comment

You must be logged in to post comments. Login now

Posted by Mike Spear


I am the Communications Director for Genome Alberta and we manage this application. In my past life I was a journalist and manager with the CBC. You can find my genome posted at

0 people like this

Be the first to like this